ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
M

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies

By ASH 2022 Conference Coverage FEATURING Mazyar Shadman
By ASH 2022 Conference Coverage FEATURING Mazyar Shadman
136 views
December 19, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lymphoma
05:34
ASH 2022 Conference Coverage

ASH 2022 Patient Reports Outcomes & Health-Related Quality of Li…

Feat. Y. Linhares
05:08
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Mara…

Feat. Y. Linhares
07:06
ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Study: Outcomes of Subsequent Anti-Lymphoma …

Feat. A. Ghobadi
06:31
ASH 2022 Conference Coverage

ASH 2022 Results From a Prespecified Analysis of the Pivotal Phase I…

Feat. D. Jagadeesh
12:39
ASH 2022 Conference Coverage

ASH 2022 Five-Year Survival Results From REMoDL-B: Outcomes in DLBCL…

Feat. A. Davies
08:04
ASH 2022 Conference Coverage

ASH 2022 Results from BRUIN: A Phase 1/2 Study of Pirtobrutinib, a H…

Feat. N. Shah
08:54
ASH 2022 Conference Coverage

ECOG-ACRIN E1411: A Randomized Phase 2 Trial of First-Line Bendamust…

Feat. M. Smith
04:07
ASH 2022 Conference Coverage

ASH 2022 Anti-CD19 CAR T-Cell Therapy for Patients With Richter Synd…

Feat. R. Guieze
10:17
ASH 2022 Conference Coverage

ASH 2022 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenali…

Feat. C. Melani
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
12:50
ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

Feat. J. Castillo
07:49
ASH 2022 Conference Coverage

ASH 2022 High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS In…

Feat. N. Epperla
06:12
ASH 2022 Conference Coverage

ASH 2022 Phase 1b/2a Study Results From Dose-Escalation: AZD4573 (CD…

Feat. P. Strati
14:28
ASH 2022 Conference Coverage

ASH 2022 CNS Prophylaxis in Aggressive B-Cell Lymphoma

Feat. K. Cwynarski
06:35
ASH 2022 Conference Coverage

Results From a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-…

Feat. N. Shah
10:36
ASH 2022 Conference Coverage

The CAR-HEMATOTOX Score Identifies Patients at High Risk for Hematol…

Feat. K. Rejeski
05:04
ASH 2022 Conference Coverage

ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety…

Feat. J. Westin
08:34
ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

Feat. M. Shadman
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
08:15
ASH 2022 Conference Coverage

ASH 2022: Glofitamab Monotherapy Induces High Complete Response Rate…

Feat. T. Phillips
06:01
ASH 2022 Conference Coverage

ASH 2022 Outcomes of R/R Double Hit Lymphoma: A Multicenter Observat…

Feat. S. Desai
12:52
ASH 2022 Conference Coverage

ASH 2022 on the Phase Ib/II Study of Polatuzumab Vedotin + Obinutuzu…

Feat. C. Diefenbach
05:55
ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Trial Updates: Association of Metabolic Tumo…

Feat. F. Locke
07:02
ASH 2022 Conference Coverage

ASH 2022 Results of the Phase II Radvax Trial: Low-Dose RT With Nivo…

Feat. M. LaRiviere